country

Change Language

EN - English
FR - Français
DE - Deutsch
ES - Español
JA - 日本語
KO - 한국어

Country or Region:

United States

Product Name	Size / Unit Price	Qty

Total: USD 0.00 Checkout

Cat. No.: HY-187396

Copy Link Print Information

FD1-C10-CB

FD1-C10-CB is a PROTAC degrader targeting the BRD4 protein. FD1-C10-CB binds to FEM1B to form a ternary complex with BRD4, achieving FEM1B-dependent degradation of BRD4 via the ubiquitin-proteasome system. FD1-C10-CB binds to CD36 to mediate endocytic cellular delivery, thereby enhancing its degrading activity. FD1-C10-CB mediates protein degradation through the Cullin-dependent ubiquitin-proteasome pathway, rather than the lysosomal autophagy pathway. FD1-C10-CB induces a decrease in BRD4 protein levels, and its degrading activity is competitively inhibited by FL47 or JQ1. FD1-C10-CB can be used in the research of breast cancer and osteosarcoma.
(Pink: BRD4 ligand (HY-78695); Blue: FEM1B E3 ligase ligand; Black: linker).

For research use only. We do not sell to patients.

Formula: C₆₄H₈₅Cl₂N₉O₉S
Molecular Weight:1227.39

Storage:

Please store the product under the recommended conditions in the Certificate of Analysis.

FD1-C10-CB Chemical Structure

Price

Stock

Quantity

Amount: USD 0.00

* Please select Quantity before adding items.

Use of MCE Products

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- IC₅₀ & Target
- In Vitro
Chemical Information
Purity & Documentation
References
Calculators
Help & FAQs
Classifications
Bioz

Biological Activity

Description

FD1-C10-CB is a PROTAC degrader targeting the BRD4 protein. FD1-C10-CB binds to FEM1B to form a ternary complex with BRD4, achieving FEM1B-dependent degradation of BRD4 via the ubiquitin-proteasome system. FD1-C10-CB binds to CD36 to mediate endocytic cellular delivery, thereby enhancing its degrading activity. FD1-C10-CB mediates protein degradation through the Cullin-dependent ubiquitin-proteasome pathway, rather than the lysosomal autophagy pathway. FD1-C10-CB induces a decrease in BRD4 protein levels, and its degrading activity is competitively inhibited by FL47 or JQ1. FD1-C10-CB can be used in the research of breast cancer and osteosarcoma^[1]. (Pink: BRD4 ligand (HY-78695); Blue: FEM1B E3 ligase ligand; Black: linker).

IC₅₀ & Target^[1]

BRD4

All PROTACs Isoforms :

All Epigenetic Reader Domain Isoforms :

In Vitro

FD1-C10-CB (10 μM; unspecified time course) mediates FEM1B-dependent BRD4 degradation in HEK293T cells via the ubiquitin-proteasome system, with enhanced activity relative to FD1 that relies on CD36-mediated endocytosis^[1].
FD1-C10-CB effectively degrades BRD4 in MDA-MB-231 and HOS cells with greater efficacy than FD1^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Western Blot Analysis^[1]

Cell Line:

HEK293T cells, FEM1B-knockout HEK293T cells
Concentration:

10 μM (inhibitor/competitor experiments); multiple concentrations (dose-dependent analysis)
Incubation Time:

1-24 h
Result:

Induced concentration- and time-dependent degradation of BRD4, with significantly improved DC₅₀ and Dₘₐₓ values compared to the parent compound FD1.
Abrogated BRD4 degradation in FEM1B-knockout cells.
Inhibited BRD4 degradation when co-administered with proteasome inhibitor MG132, neddylation inhibitor MLN4924, CD36 inhibitor SMS121, and excess FL47 or JQ1.
Left BRD4 degradation unaffected by lysosomal inhibitors bafilomycin A1 or chloroquine.

Chemical Information

Molecular Weight 1227.39
Formula C₆₄H₈₅Cl₂N₉O₉S
SMILES

ClCC(N1CCN(CCCNC([C@]23C[C@@H]4C[C@@H](C[C@@](C(NC5=CC(OCCNC(C[C@H]6C7=NN=C(C)N7C(SC(C)=C8C)=C8C(C9=CC=C(Cl)C=C9)=N6)=O)=CC(OC(CCCCCCCCCCC(OC(C)(C)C)=O)=O)=C5)=O)(C4)C3)C2)=O)CC1)=O
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.

Purity & Documentation

Handling Instructions (2659 KB)

References

[1]. Xu L, et al. Structure-Guided Discovery of Novel Dual-Site FEM1B Ligands and Assessment of Their Use in Targeted Protein Degradation. Journal of medicinal chemistry. 2026 Jul 15. [Content Brief]

Calculators

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Bioz

Keywords

MOQ

Minimum order quantity

100 mg

Get Quote In-stock

Other size

Get Quote

Amount: USD 0.00

Biological Activity
- Description
- IC₅₀ & Target
- In Vitro
Chemical Information
Purity & Documentation
References

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Product Name:
CAS No.:
Species:
Purity:
Quantity:

FD1-C10-CB

All PROTACs Isoforms

All Epigenetic Reader Domain Isoforms